Abuse-Deterrent Formulations of Opioid Analgesics

Pain Practice

Volumn 14, Issue 3, 2014, Pages 204-206

  Pergolizzi, Joseph V ^a,b,c   Lequang, Jo Ann ^a,d  

^a Pain Center   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NEMA Research Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MORPHINE; OPIATE; OXYCODONE; PRESCRIPTION DRUG;

CHRONIC PAIN; DRUG ABUSE; DRUG FORMULATION; DRUG MISUSE; DRUG PREFERENCE; DRUG USE; EDITORIAL; EXERCISE; HUMAN; LIFESTYLE MODIFICATION; PATIENT EDUCATION; PRESCRIPTION; SUBSTANCE ABUSE;

ANALGESICS, OPIOID; CHEMISTRY, PHARMACEUTICAL; HUMANS; OPIOID-RELATED DISORDERS;

EID: 84897602018     PISSN: 15307085     EISSN: 15332500     Source Type: Journal    
DOI: 10.1111/papr.12093     Document Type: Editorial

References (16)

1. Pergolizzi JV, Raffa RB, Pergolizzi JS, Taylor R. Non-analgesic effects of opioids: factors relevant to opioid abuse and abuse- deterrent formulations. Curr Pharm Des 2012;18:6109-6115.
2. Budman SH, Grimes Serrano JM, Butler SF. Can abuse deterrent formulations make a difference? Expectation and speculation Harm Reduct. J. 2009;6:8.
3. Young A, Havens J, Leukefeld C. Route of administration for illicit prescription opioids: a comparison of rural and urban drug users. Harm Reduct. J. 2010;15:24.
4. Zacny JP. Characterizing the subjective, psychomotor, and physiological effects of a hydrocodone combination product (Hycodan) in non-drug-abusing volunteers. Psychopharmacology 2003;165:146-156.
5. Zacny JP, Gutierrez S. Characterizing the subjective, psychomotor, and physiological effects of oral oxycodone in non-drug-abusing volunteers. Psychopharmacology 2003;170:242-254.
6. Zacny JP, Apfelbaum SM, Perkins KA. Modulating roles of smoking status and sex on oxycodone-induced nausea and drug liking. Exp. Clin. Psychopharmaco. 2013;21:103-111.
7. Butler SF, Benoit C, Budman SH, et al. Development and validation of an Opioid Attractiveness Scale: a novel measure of the attractiveness of opioid products to potential abusers. Harm Reduct. J. 2006;3:5.
8. Butler SF, Fernandez KC, Chang A, et al. Measuring attractiveness for abuse of prescription opioids. Pain Med. 2010;11:67-80.
9. Katz NP, Adams EH, Chilcoat H, et al. Challenges in the development of prescription opioid abuse-deterrent formulations. Clin J Pain 2007;23:648-660.
10. Brownstein JS, Green TC, Cassidy TA, Butler SF. Geographic information systems and pharmacoepidemiology: using spatial cluster detection to monitor local patterns of prescription opioid abuse. Pharmacoepidemiol Drug Saf 2010;19:627-637.
11. Darke S, Mills KL, Ross J, Williamson A, Havard A, Teesson M. The ageing heroin user: career length, clinical profile and outcomes across 36 months. Drug Alcohol Rev. 2009;28:243-249.
12. Unick GJ, Rosenblum D, Mars S, Ciccarone D. Intertwined epidemics: national demographic trends in hospitalizations for heroin- and opioid-related overdoses, 1993-2009. PLoS ONE 2013;8:e54496.
13. Cone EJ, Giordano J, Weingarten B. An iterative model for in vitro laboratory assessment of tamper deterrent formulations. Drug Alcohol Depend 2013;131:100-105.
14. Butler SF, Venuti SW, Benoit C, Beaulaurier RL, Houle B, Katz N. Internet surveillance: content analysis and monitoring of product-specific internet prescription opioid abuse-related postings. Clin J Pain 2007;23:619-628.
15. FDA. Guidance for Industry: Abuse-Deterrent Opioids, Evaluation and Labeling. 2013 http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM334743.pdf (accessed April 25, 2013)
16. H.R. 486: Stop Tampering of Prescription Pill Act of 2013. 2013 http://www.govtrack.us/congress/bills/113/hr486 (accessed April 24, 2013)